中华肝脏病杂志最新文献

{"title":"[A case of chronic hepatitis B with low-level viremia treated with sequential treatment of tenofovir amibufenamide].","authors":"Q Liang","doi":"10.3760/cma.j.cn501113-20240905-00480","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240905-00480","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"70-72"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Real-world data of tenofovir amibufenamide therapy for treatment-naïve patients with chronic hepatitis B].","authors":"J R Zheng, B Feng, Y D Xie","doi":"10.3760/cma.j.cn501113-20240831-00453","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00453","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"65-67"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B].","authors":"Y Li, W Y Wang","doi":"10.3760/cma.j.cn501113-20240831-00457","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00457","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B. <b>Method:</b> Forty patients with chronic hepatitis B who had poor responses to entecavir, admitted to Linyi Central Hospital from July 2021 to July 2024, were selected as the study subjects. Among them, 18 and 22 cases were hepatitis B e antigen (HBeAg) negative and positive, respectively. All patients were treated using tenofovir amibufenamide tablets. The differences in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to treatment, at 12 and 24 weeks of treatment, were compared between HBeAg-negative and positive patients.The hepatitis B virus (HBV) DNA negative conversion rate was compared after 12 and 24 weeks of treatment between HBeAg-negative and positive patients. Statistical analysis was performed using <i>t</i>-test, one-way ANOVA, LSD-<i>t</i> test, and <i>χ</i>² test according to different data. <b>Result:</b> ALT and AST levels were higher in HBeAg-positive than those of HBeAg-negative patients (<i>P</i>＜0.05) prior to treatment. ALT and AST levels were lower in HBeAg-negative and HBeAg-positive patients compared to pre-treatment, while those of HBeAg-negative patients were lower than those of HBeAg-positive patients (<i>P</i>＜0.05) after 12 and 24 weeks of treatment. The HBV DNA negative conversion rate was lower in HBeAg-positive patients than that of HBeAg-negative patients (<i>P</i>＜0.05) after 12 weeks of treatment. There was no statistically significant difference in the HBV DNA conversion rate between HBeAg-positive and HBeAg-negative patients after 24 weeks of treatment (<i>P</i>>0.05). <b>Conclusion:</b> Switching to tenofovir amibufenamide tablets can improve liver function and promote HBV DNA negative conversion with poor response to entecavir in patients with chronic hepatitis B, with better therapeutic effect in HBeAg-negative patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide inhibiting low-level viremia and delaying the progression of liver cirrhosis: a case report].","authors":"C Y Zhao, C F Nie, Z H Zhao","doi":"10.3760/cma.j.cn501113-20240829-00404","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240829-00404","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Two cases of patients with hepatitis B e antigen-positive chronic hepatitis B initially treated with tenofovir amibufenamide].","authors":"J H Xin, J J Fan, Y Chen","doi":"10.3760/cma.j.cn501113-20240930-00522","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240930-00522","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"78-80"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Evaluation of the efficacy and safety profile of tenofovir amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis].","authors":"K Y Hao, X Jiang, Y Dong, H N Sun, Y C Yu","doi":"10.3760/cma.j.cn501113-20240904-00475","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240904-00475","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the efficacy and safety profile of tenofovir amibufenamide (TMF) at 48 weeks in patients with hepatitis B virus-related compensated and decompensated stage cirrhosis. &lt;b&gt;Methods:&lt;/b&gt; Patients with treatment-naïve or treatment-experienced hepatitis B virus-related cirrhosis with nucleos(t)ide analogues (NA) who met the inclusion and exclusion criteria from 2022 to 2024 were retrospectively collected and divided into the tenofovir amibufenamide group (TMF, &lt;i&gt;n&lt;/i&gt;=25) and the tenofovir alafenamide fumarate group (TAF, &lt;i&gt;n&lt;/i&gt;=14). The conditional changes in hepatitis B virus DNA (HBV DNA), hepatitis B surface antigen (HBsAg), liver function indexes, serum creatinine (Cr), estimated glomerular filtration rate (eGFR), serum phosphorus, blood lipid profiles, and other variables were compared between and within the groups at baseline and 48 weeks. The &lt;i&gt;t&lt;/i&gt;-test or Kruskal-Wallis &lt;i&gt;H&lt;/i&gt; test was used to compare the measurement data among the groups. The &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test was used for the enumeration data. &lt;b&gt;Results:&lt;/b&gt; There were no statistically significant differences in baseline, age, gender, proportion of compensated/decompensated stage cirrhosis, proportion of NA-naive/treatment experienced, liver function indexes, serum Cr, and eGFR between the two groups (&lt;i&gt;P&lt;/i&gt;&gt;0.05). There was no statistically significant difference in the proportion of patients with HBV DNA&lt;30 IU/ml (&lt;i&gt;P&lt;/i&gt;=1.00) between the two groups, regardless of whether they were NA-naive (&lt;i&gt;P&lt;/i&gt;=0.52) or treatment experienced (&lt;i&gt;P&lt;/i&gt;=1.00) at 48 weeks. There was no statistically significant difference in HBsAg levels between the TMF and TAF groups (&lt;i&gt;P&lt;/i&gt;=0.18) at 48 weeks. There was no statistically significant difference in the decline of HBsAg within each group (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The levels of alanine aminotransferase (&lt;i&gt;P&lt;/i&gt;&lt;0.001) and aspartate aminotransferase (&lt;i&gt;P&lt;/i&gt;=0.045) were significantly lower at 48 weeks than those at baseline, while the albumin level was higher than that at baseline (&lt;i&gt;P&lt;/i&gt;=0.004) among the TMF group. There were no statistically significant differences in the rest of the liver function indicators among the TMF and the TAF groups between baseline and 48 weeks (&lt;i&gt;P&lt;/i&gt;&gt;0.05). There were no statistically significant differences in Cr (&lt;i&gt;P&lt;/i&gt;=0.34) and eGFR levels (&lt;i&gt;P&lt;/i&gt;=0.60) at 48 weeks between the TMF and TAF groups.There were no statistically significant differences in Cr (&lt;i&gt;P&lt;/i&gt;=0.89) and eGFR levels (&lt;i&gt;P&lt;/i&gt;=0.57) at 48 weeks in patients aged&lt;40 years (&lt;i&gt;n&lt;/i&gt;=8) compared with baseline in the TMF group. There were no statistically significant differences (&lt;i&gt;P&lt;/i&gt;=0.09, &lt;i&gt;P&lt;/i&gt;=0.13) in patients with similar aged≥40 years (&lt;i&gt;n&lt;/i&gt;=17). The reduction in Cr level (&lt;i&gt;P&lt;/i&gt;&lt;0.001) and the increase in eGFR (&lt;i&gt;P&lt;/i&gt;&lt;0.001) at 48 weeks were statistically significant in patients aged&lt;40 years (&lt;i&gt;n&lt;/i&gt;=3) among the TAF group. There were no statistically significant differences in Cr","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"19-29"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of acute-on-chronic liver failure related to hepatitis B treated with tenofovir amibufenamide].","authors":"C C Zhang, T T Yuan, Q Yang","doi":"10.3760/cma.j.cn501113-20240831-00428","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00428","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"50-51"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of chronic hepatitis B with a high viral load treated with tenofovir amibufenamide].","authors":"Y N Yan, X F Yan, G X Jin, W J Deng, Y S Zheng, X Y Wang","doi":"10.3760/cma.j.cn501113-20240831-00431","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00431","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"85-86"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of hepatitis B virus-related hepatocellular carcinoma with low-level viremia achieved seronegative conversion with entecavir combined with tenofovir amibufenamide].","authors":"W G Ren, J Li, S X Zhao, L D Liu, X X Zhang, Y M Nan","doi":"10.3760/cma.j.cn501113-20240930-00516","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240930-00516","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Observation on the efficacy of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide in the treatment of chronic hepatitis B].","authors":"Z Hua","doi":"10.3760/cma.j.cn501113-20240917-00467","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240917-00467","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the effect of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide (TMF) and TMF monotherapy on the immune functions of peripheral blood lymphocytes and the inhibition of HBV replication for chronic hepatitis B (CHB). <b>Methods:</b> Seventy CHB cases were randomly divided into a treatment and a control group based on the hepatoprotective therapy, with 36 and 34 cases in the treatment and control groups, respectively. The treatment group was treated with oral tenofovir amibufenamide 25 mg once a day, in combination with Zhenqi Fuzheng capsule 1.4 g three times a day. The control group was treated with oral TMF 25 mg once a day. The treatment course was compared at 48 weeks in both groups. <b>Results:</b> Peripheral blood lymphocyte immune function indicators: The CD4⁺ cells, CD4⁺/CD8⁺ ratio, and natural killer cell values in the treatment group were higher than those in the control group at 48 weeks of treatment (<i>P</i><0.05). The treatment group had a serum HBeAg negative conversion rate of 50.0% at 48 weeks of treatment, while the control group had a rate of 26.3%. The difference between the two groups was statistically significant (<i>χ²</i>=6.98, <i>P</i><0.05). HBV DNA load: The decrease in HBV DNA load in the two groups was statistically significant compared with the baseline HBV DNA value at 24 and 48 weeks of treatment (<i>P</i><0.05). <b>Conclusion:</b> Zhenqi Fuzheng capsules combined with TMF therapy are superior for regulating immune function and reducing HBV DNA load and HBeAg-negative seroconversion rates compared to TMF alone.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"10-13"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}